Mink Therapeutics
Yahoo Finance • last year
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797 demonstrates potential beyond cancer, with impr... Full story
Yahoo Finance • last year
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioningAgenT-... Full story
Yahoo Finance • last year
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural k... Full story
Yahoo Finance • last year
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural... Full story
Yahoo Finance • last year
MiNK Therapeutics to Participate in September Investor Conferences
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural kil... Full story
Yahoo Finance • 2 years ago
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC modelsIND enabling studies underway; IND filing on track for 2024 NEW YORK, May 18, 2023 (GLOBE NEWSWIRE)... Full story
Yahoo Finance • 2 years ago
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists without lymphodepletion.Initiating phase 1/2 expansion studies in NSCLC and gastric can... Full story
Yahoo Finance • 2 years ago
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023 AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023Allogeneic CAR platform demonstrates... Full story
Yahoo Finance • 2 years ago
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural... Full story
Yahoo Finance • 3 years ago
MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022GMP manufacturing launch in 1H 2022 with target 10,000 doses/yrBCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022Ended First Quarter... Full story
